EyeGate Pharmaceuticals to Present at the Noble Financial Capital Markets’ 13th Annual Investor Conference
January 24, 2017 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 24, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Pharma Awarded Canadian Patent for Proprietary Iontophoretic Formulation and Use of the Formulation for Ocular Delivery of Dexamethasone Phosphate
January 23, 2017 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and...
EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437
January 09, 2017 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Reports Positive Data from Third Stage of Phase 1b/2a Clinical Trial of EGP-437 in Cataract Surgery Patients
December 05, 2016 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 05, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
FDA Confirms a 510(k) De Novo Path for EyeGate’s Device, the Ocular Bandage Gel, Following Pre-Submission Meeting
November 17, 2016 16:01 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on...
EyeGate Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update
November 02, 2016 09:20 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on...
EyeGate Pharmaceuticals to Present at the 2016 Aegis Capital Conference
September 21, 2016 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 21, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (Nasdaq:EYEG), (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense
September 13, 2016 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 13, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437
September 12, 2016 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Pharmaceuticals to Present at the 18th Annual Rodman and Renshaw Global Investment Conference
September 06, 2016 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- EYEG (Nasdaq:EYEG), (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products...